| Dear Fellow Trader, |
| I hope this trading day has been good to you! I am sending you trade ideas for tomorrow. So you can have enough time to take action on our trades ideas. |
🤑 Could NNVC Be the Next Biotech Giant? (ad)*
NV-387, NanoViricides’ breakthrough antiviral, is advancing to Phase 2 with broad potential across MPox, RSV, flu, and biodefense. With strong safety data and Zacks assigning a $7 valuation, NNVC is entering a pivotal growth window.
🎯 Discover why this platform could redefine antiviral medicine. |
| Options Trade Ideas (Volatility Rush Strategy) |
| The basic option trade idea is to buy an at-the-money straddle while the options premium is cheap. |
| In assessing this trade, you need to do your homework to ensure you are not paying too much for the straddle. |
| As the earnings date approaches, the implied volatility (IV) should increase, resulting in greater price movement. |
| However, be aware that you should close your position before the announcement comes out in order to maximize your profit potential. That's because once earnings are released, IV will fall dramatically, which will greatly reduce your opportunity to profit on the trade. |
| The stocks (with Weekly Options) below are announcing earnings in next few weeks. Our proprietary volatility algorithm suggests these stocks are likely to experience high volatility as earnings day approaches. |
| |
|
 | Before Market Open |  | After Market Close | |
| *Predicted Volatility % based on our Proprietary Volatility Predication Model. We are expecting that stock price will likely to reach % in either direction by the end of next trading session after Earnings are released and not necessarily the closing volatility %. |
With a $7 Valuation, NNVC Could Disrupt the Biotech Space in 2026 (ad)*
NNVC is heating up fast. NV-387 is moving into Phase 2 trials — and Zacks Small Cap Research now assigns a $7 target, citing its strong safety profile and broad antiviral potential. With government procurement, biodefense demand, and non-dilutive BARDA funding all on the table, NanoViricides could be on the verge of a multi-billion-dollar breakthrough.
Get the full story before Wall Street catches on. |
🔮 Analysts Forecast 5x Upside: A Game-Changing Biotech Story Unfolding (ad)*
This emerging antiviral innovator is capturing Wall Street’s attention as its flagship drug, NV-387, moves toward human trials targeting MPox, measles, and major respiratory viruses. Built on a revolutionary nanomedicine platform designed to destroy viruses before they infect cells, NV-387 is being positioned for multi-billion-dollar opportunities in biodefense and global health. With rising outbreaks and Zacks highlighting explosive upside, this could be one of 2026’s most electrifying biotech stories.
🏆 This could be the top name in biotech to watch in 2026! |
| At StockEarnings, we're really excited to help you trade more confidently. To that end, we're constantly developing new content to go alongside our platform insights, which will further our mission to help you become a better trader. |
| To your trading success, |
| Hiral Ghelani |
| Founder & CEO |
| StockEarnings, Inc |
| 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA |
| W: 877.6.STOCKS (Mon to Sat | 9am to 5pm EST | Feel Free to Call Us) |
| |
|
| (ad)* This message is a PAID ADVERTISEMENT for NanoViricides, Inc (NYSE: NNVC) from Interactive Offers. StockEarnings, Inc. has received a fixed fee of $4000 from Interactive Offers for multiple Dedicated Email Sends, Newsletter Sponsorships and SMS Sends between Dec 01, 2025 and Dec 05, 2025. Other than the compensation received for this advertisement sent to subscribers, StockEarnings and its principals are not affiliated with either NanoViricides, Inc (NYSE: NNVC) or Interactive Offers. StockEarnings and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither StockEarnings nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from StockEarnings to buy or sell any security. StockEarnings has not evaluated the accuracy of any claims made in this advertisement. StockEarnings recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding NanoViricides, Inc (NYSE: NNVC) on EQUISCREEN, LLC website for additional information about the relationship between Interactive Offers and NanoViricides, Inc (NYSE: NNVC).
StockEarnings, Inc (SE) is a research service not owned or managed by registered brokers and therefore this site does not make any investment recommendations. The information provided in this newsletter is not guaranteed as to the accuracy or completeness. Each user of SE chooses to do trades at their sole discretion and risk. SE is not responsible for gains/losses that may result in the trading of these securities. This newsletter includes paid advertisements. The source of all third-party content in which SE receives some sort of compensation, is clearly and prominently identified herein as "ad" or "Sponsored". Although we have sent you these advertisements, SE does not specifically endorse any third-party product nor is it responsible for the content of the advertisement or the experience with the third-party advertiser. Furthermore, we make no guarantee or warranty about what is advertised. All investments involve risk, losses may exceed the principal invested, and the past performance of a security, industry, sector, market, or financial product does not guarantee future results or returns. Please click here for SE Disclaimers. StockEarnings Inc 33 SE 4th St, Suite 100, Boca Raton, FL 33432 USA | W: 877.6.STOCKS |
Unsubscribe
Today's Bonus Content: What Insiders Are Doing Before 2026 Next Big Move
|
0 Response to "🚀 Your Premium Trade Alerts (Dec 1)"
Post a Comment